ERBB2 and adenocarcinoma: The increased potential for the formation of EGFR-HER2 heterodimers, which induce a stronger and more sustained signal than EGFR homodimers (Yarden and Sliwkowski, 2001), could result in greater reliance on this signalling network in adenocarcinoma and consequently greater sensitivity to inhibition of EGFR signalling.